A Phase 1, Open Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-007 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer - Stand Up To Cancer

Blog

Posted October 11, 2019

A Phase 1, Open Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-007 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.